Veradigm Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de Veradigm disminuyan en un 26.7% al año. Se prevé que el BPA aumente en un 0.9% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

0.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	28.6%
Tasa de crecimiento de los ingresos	-26.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 22

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Jan 04

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Dec 03

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Sep 28

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Sep 17

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Aug 24

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Jul 31

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Jun 15

We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)

May 03

These 4 Measures Indicate That Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Using Debt Reasonably Well

Apr 12

Allscripts Healthcare Solutions' (NASDAQ:MDRX) Robust Earnings Might Be Weaker Than You Think

Mar 04

Allscripts Healthcare Solutions: Fundamentals Are Improving, But Consistency Needs To Be Established

Feb 27

Previsiones de crecimiento de beneficios e ingresos

OTCPK:MDRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	690	N/A	N/A	N/A	1
12/31/2024	649	N/A	N/A	N/A	3
12/31/2023	625	N/A	N/A	N/A	3
12/31/2022	617	-4	N/A	N/A	2
9/30/2022	1,529	116	82	161	N/A
6/30/2022	1,522	125	107	189	N/A
3/31/2022	1,512	148	-91	-11	N/A
12/31/2021	1,503	134	-154	-75	N/A
9/30/2021	806	-14	-373	-319	N/A
6/30/2021	1,027	-48	-388	-322	N/A
3/31/2021	1,255	-96	-183	-98	N/A
12/31/2020	1,503	-133	-212	-107	N/A
9/30/2020	1,428	-143	-15	84	N/A
6/30/2020	1,507	-134	-44	67	N/A
3/31/2020	1,582	-263	-79	37	N/A
12/31/2019	1,633	-238	-74	46	N/A
9/30/2019	1,763	-197	-119	20	N/A
6/30/2019	1,751	-203	-138	-1	N/A
3/31/2019	1,748	34	-129	15	N/A
12/31/2018	1,618	-39	-66	68	N/A
9/30/2018	1,516	70	73	188	N/A
6/30/2018	1,533	54	105	237	N/A
3/31/2018	1,518	-187	120	262	N/A
12/31/2017	1,498	-183	122	279	N/A
9/30/2017	1,714	-210	67	257	N/A
6/30/2017	1,657	-191	65	246	N/A
3/31/2017	1,618	-48	105	269	N/A
12/31/2016	1,386	31	145	269	N/A
9/30/2016	1,470	-2	153	268	N/A
6/30/2016	1,432	3	N/A	255	N/A
3/31/2016	1,397	10	N/A	229	N/A
12/31/2015	1,386	-2	N/A	212	N/A
9/30/2015	1,382	-21	N/A	180	N/A
6/30/2015	1,373	-41	N/A	154	N/A
3/31/2015	1,372	-56	N/A	141	N/A
12/31/2014	1,378	-66	N/A	103	N/A
9/30/2014	1,388	-85	N/A	70	N/A
6/30/2014	1,373	-108	N/A	68	N/A
3/31/2014	1,366	-113	N/A	63	N/A
12/31/2013	1,373	-104	N/A	81	N/A
9/30/2013	1,373	-108	N/A	121	N/A
6/30/2013	1,404	-49	N/A	140	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de MDRX es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de MDRX crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de MDRX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de MDRX disminuyan en los próximos 3 años (-26.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de MDRX disminuyan en los próximos 3 años (-26.7% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MDRX se prevé que sea elevada dentro de 3 años.

Veradigm Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Price target decreased by 7.1% to US$19.19

Price target decreased by 9.1% to US$20.07

Recent updates

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from Listing

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Veradigm Inc. (OTCPK:MDRX) completed the acquisition of Cascade Bio, Inc

Veradigm Inc. announced delayed annual 10-K filing

Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite Index

Veradigm Receives Expected Delisting Notice from Nasdaq

Investor sentiment deteriorates as stock falls 18%

Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Robbins Geller Rudman & Dowd LLP Files Amended Class Action Lawsuit Against Veradigm Inc

Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm Inc

Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

Veradigm Inc. Announces CEO Changes

Veradigm Inc. Announces CEO Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q

Veradigm Inc. announced delayed 10-Q filing

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Veradigm to Simplify Patient Payment Journey with Veradigm Intelligent Payments

Veradigm Inc. Announces Receipt of Nasdaq Stay Extension

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Veradigm Inc. announced delayed 10-Q filing

Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)

Veradigm Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Veradigm Inc. announced delayed 10-Q filing

Price target decreased by 7.1% to US$19.19

Price target decreased by 9.1% to US$20.07

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Investor sentiment deteriorates as stock falls 15%

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Consensus EPS estimates fall by 11%

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Veradigm Inc. to Report Q4, 2022 Results on Feb 23, 2023

LeanTaaS Inc. acquired Hospital IQ, Inc.

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Insider notifies of intention to sell stock

Independent Director recently sold US$797k worth of stock

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS misses analyst expectations

Allscripts Healthcare Solutions, Inc. Provides Revenue Guidance for the Year 2022

Allscripts Healthcare Solutions, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Chief Financial Officer recently sold US$116k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer recently sold US$70k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.16 in 2Q 2021)

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Allscripts Healthcare Solutions, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Director notifies of intention to sell stock

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director recently sold US$1.3m worth of stock

Independent Director recently sold US$101k worth of stock